These are top 10 stocks traded on the Robinhood UK platform in July
On Tuesday, H.C. Wainwright maintained a positive outlook on Arrowhead Pharma (NASDAQ:ARWR), reaffirming a Buy rating and an $80.00 price target for the stock. Currently trading at $15.21, the stock has seen significant pressure, down 48% over the past year and trading near its 52-week low of $15.11. The endorsement follows Arrowhead’s announcement of promising top-line results from a recent clinical trial. According to InvestingPro data, five analysts have recently revised their earnings estimates upward for the upcoming period.
On Monday, Arrowhead revealed findings from Part 2 of their Phase 1/2 trial, which is assessing ARO-C3, a small interfering RNA (siRNA) therapeutic candidate. The treatment is aimed at reducing liver production of complement component 3 (C3) to address complement-mediated renal diseases. The results indicated that ARO-C3 achieved significant and prolonged reductions in alternative pathway complement activity and proteinuria, a key indicator of renal injury, over a 24-week period in patients with IgA nephropathy (IgAN). While the company maintains strong liquidity with a current ratio of 6.09, InvestingPro analysis indicates the company is quickly burning through cash, which is typical for clinical-stage biotech companies.
IgAN is recognized as the most prevalent glomerular disease on a global scale and is associated with a substantial risk of progressing to end-stage renal disease over a patient’s lifetime. The positive outcomes of the trial have reinforced confidence in the potential of ARO-C3 to become a leading treatment for complement-mediated diseases.
The analyst from H.C. Wainwright commented on the results, noting the implications for ARO-C3’s future. "The top-line data show that ARO-C3 led to deep and sustained reductions through Week 24 in alternative pathway complement activity and proteinuria in patients with IgA nephropathy, which is the most common glomerular disease worldwide and carries a high lifetime risk of progression to end-stage renal disease," the analyst stated. "Importantly, these data support our confidence in ARO-C3’s potential to become a blockbuster program in complement-mediated diseases."
The continued endorsement by H.C. Wainwright reflects the firm’s belief in the therapeutic candidate’s success and Arrowhead Pharma’s prospects in the pharmaceutical market. The reiterated price target and rating are based on the recent clinical advancements and the anticipated impact of ARO-C3 on treating complement-mediated renal diseases. With a market capitalization of $1.92 billion and analysts projecting 37% revenue growth for FY2025, investors seeking deeper insights can access comprehensive analysis and 12 additional ProTips through InvestingPro’s detailed research reports.
In other recent news, Arrowhead Pharmaceuticals has reported promising results from its Phase 1/2 study of ARO-C3, a treatment for IgA nephropathy. The study demonstrated significant reductions in key disease markers, with a mean sustained reduction in complement component 3 (C3) of over 87% and a 41% reduction in urine protein-to-creatinine ratio by week 24. Additionally, Arrowhead has completed a transaction with Sarepta Therapeutics (NASDAQ:SRPT), resulting in approximately $1.4 billion in upfront and near-term payments. This financial boost is expected to advance Arrowhead’s cardiometabolic disease pipeline, with a focus on the APOC3 inhibitor program.
Goldman Sachs has maintained a Neutral rating for Arrowhead, citing the need for longer-term data to fully assess ARO-C3’s potential. Meanwhile, RBC Capital Markets has sustained an Outperform rating, highlighting the strategic focus on cardiometabolic programs following the Sarepta deal. Arrowhead is also progressing with RNA interference-based treatments for obesity, with clinical trials for ARO-INHBE and ARO-ALK7 underway.
The company has launched a new website and white paper to support individuals with familial chylomicronemia syndrome (FCS), part of its ongoing commitment to the FCS community. These developments reflect Arrowhead’s strategic initiatives in expanding its product pipeline and supporting patient communities. Further data and advancements are anticipated in the coming years, as the company continues to focus on innovative RNAi-based therapeutics.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.